Supriya Lifescience Q2 PAT at Rs 504 mn, revenue up 20% YoY
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 3.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Supriya Lifescience posted Q2 FY26 revenue from operations at Rs 1,998.33 million, up 20.3 percent year-on-year from Rs 1,661.02 million. Net profit for the quarter came in at Rs 504.27 million versus Rs 461.49 million, a rise of about 9.3 percent. For the half year, revenue grew 5.6 percent to Rs 3,449.07 million while PAT eased 6.1 percent to Rs 852.17 million. Quarterly EPS stood at Rs 6.27 against Rs 5.71. Operating margins show signs of compression versus the year-ago period.
Strong quarterly revenue growth lifts sentiment, but half-year PAT decline and margin compression may weigh on near-term stock reaction.